26:2370–2377 21.Morikawa T, Yoshida M 1995 A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biop-harm Stat 5:297–306 22.Hochberg Y 1988 A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800–802 23.Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group2010 Efficacy and safety of exenatide once weekly versus sitagliptinor pioglitazone as an adjunct to metformin for treatment of type 2diabetes (DURATION-2): a randomised trial. Lancet 376:431–439 24.Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M 2010 Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURA-TION-3): an open-label randomised trial. Lancet 375:2234–2243 25.Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD 2004